| __timestamp | Ascendis Pharma A/S | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 20140000 |
| Thursday, January 1, 2015 | 9415000 | 37173000 |
| Friday, January 1, 2016 | 11504000 | 48616000 |
| Sunday, January 1, 2017 | 13482000 | 108488000 |
| Monday, January 1, 2018 | 25057000 | 244622000 |
| Tuesday, January 1, 2019 | 48473000 | 287000000 |
| Wednesday, January 1, 2020 | 76669000 | 354000000 |
| Friday, January 1, 2021 | 160180000 | 186000000 |
| Saturday, January 1, 2022 | 221227000 | 151000000 |
| Sunday, January 1, 2023 | 264410000 | 232600000 |
| Monday, January 1, 2024 | 284545000 | 267474000 |
Unlocking the unknown
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Ascendis Pharma A/S and Ionis Pharmaceuticals, Inc. have been navigating this financial landscape since 2014. Over the past decade, Ascendis Pharma has seen a staggering increase in SG&A expenses, growing from approximately $6 million in 2014 to over $264 million in 2023. This represents a growth rate of over 4,200%, reflecting their aggressive expansion strategy.
In contrast, Ionis Pharmaceuticals, while starting with higher SG&A costs of around $20 million in 2014, has managed a more stable trajectory, peaking at $354 million in 2020 before reducing to $232 million in 2023. This indicates a strategic shift towards cost optimization. As these companies continue to evolve, their ability to manage SG&A expenses will be pivotal in determining their long-term success.
Novo Nordisk A/S and Ionis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Amgen Inc. or Ascendis Pharma A/S: Who Manages SG&A Costs Better?
Takeda Pharmaceutical Company Limited vs Ascendis Pharma A/S: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Alnylam Pharmaceuticals, Inc. or Ascendis Pharma A/S
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Veracyte, Inc.
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Soleno Therapeutics, Inc.
Ascendis Pharma A/S or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Ascendis Pharma A/S and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Ionis Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Ionis Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.